Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...
Nephrotic Syndrome I : Introduction01:24

Nephrotic Syndrome I : Introduction

Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of fluid...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients.

Clinical nephrology·2010
Same author

Dialysis removes apolipoprotein C-I, improving very low-density lipoprotein clearance.

Kidney international·2007
Same author

Metabolic syndrome and renal failure: similarities and differences.

Panminerva medica·2006
Same author

Metabolic consequences of body size and body composition in hemodialysis patients.

Kidney international·2006
Same author

Endothelial bound lipoprotein lipase (LpL) depletion in hypoalbuminemia results from decreased endothelial binding, not decreased secretion.

Kidney international·2006
Same author

Measuring partial body potassium in the arm versus total body potassium.

Journal of applied physiology (Bethesda, Md. : 1985)·2006

Related Experiment Video

Updated: Jul 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Hyperlipidemia in chronic kidney disease.

G A Kaysen1

  • 1Division of Nephrology, Department of Medicine, University of California Davis, California 95616, USA. gakaysen@ucdavis.edu

The International Journal of Artificial Organs
|December 11, 2007
PubMed
Summary

Cardiovascular risk factors change with declining kidney function. In dialysis patients, obesity improves survival, while altered cholesterol levels like low High Density Lipoprotein cholesterol (HDL) remain critical.

Area of Science:

  • Nephrology
  • Cardiology
  • Lipidology

Background:

  • Cardiovascular disease risk and mortality escalate with diminished renal function.
  • Traditional cardiovascular risk factors are modified or superseded in patients with kidney disease.
  • Obesity's impact shifts from predicting renal function loss to predicting survival in dialysis patients.

Purpose of the Study:

  • To explore the altered cardiovascular risk profiles in patients with declining renal function and end-stage renal disease.
  • To investigate the role of specific lipoproteins, including Low Density Lipoprotein cholesterol (LDL), High Density Lipoprotein cholesterol (HDL), and Intermediate Density Lipoproteins (IDL), in cardiovascular outcomes in kidney disease.
  • To examine the mechanisms behind dyslipidemia in chronic kidney disease (CKD) and their association with mortality.

More Related Videos

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Related Experiment Videos

Last Updated: Jul 9, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

Main Methods:

  • Analysis of established cardiovascular risk factors in the context of varying degrees of renal function.
  • Evaluation of lipoprotein profiles (LDL, HDL, IDL, Lipoprotein (a)) and their correlation with mortality and survival in dialysis patients.
  • Investigation of the impact of chronic kidney disease (CKD) on lipid metabolism, including fractional catabolic rate (FCR), lecithin cholesterol ester transfer protein (LCAT) activity, and insulin resistance.

Main Results:

  • Obesity is linked to survival in dialysis patients, contrasting its role in renal function decline.
  • Low HDL and increased IDL levels are significant cardiovascular risk factors in dialysis patients, whereas LDL is not.
  • Dyslipidemia in CKD involves decreased HDL maturation, increased triglycerides (TG), and elevated Lipoprotein (a) (Lp(a)) due to reduced clearance, all associated with adverse cardiovascular outcomes.

Conclusions:

  • Cardiovascular risk assessment in kidney disease requires a shift from standard models, focusing on specific lipid abnormalities.
  • Altered HDL metabolism and increased TG-rich IDL and Lp(a) are key contributors to cardiovascular risk in CKD and dialysis patients.
  • Understanding these unique pathophysiological mechanisms is crucial for managing cardiovascular complications in patients with impaired renal function.